[S-39] Symposium 39
The concept of MOG-IgG positive diseases

[S-39-4] Pathology of MOG-IgG diseases

^○Yoshiki Takai¹, Tatsuro Misu¹, Kazuo Fujihara^1,2, Masashi Aoki¹ (1.Department of Neurology, Tohoku University Hospital, Japan, 2.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Japan)

Auto-antibodies (IgG) against myelin oligodendrocyte glycoprotein (MOG) are detected in the serum of patients with various demyelinating diseases. These patients are known to show repeated clinical episodes of inflammatory demyelinating attacks in the central nervous system. Although the associated pathogenicity and mechanism of inflammatory demyelination remains inconclusive, it is known that patients with MOG-IgG have a different clinical spectrum from those with other demyelinating diseases, such as multiple sclerosis. We conducted this symposium to understand the clinical features and the spectrum of MOG-IgG related demyelinating diseases.

Education:
2006 M.D., Tohoku University School of Medicine
2012 Ph.D. (Dr. of Medical Science), Tohoku University Graduate School of Medicine　

Career:
2012-2013 Clinical fellow in Neurology, Iwate hospital, Ichinoseki, Iwate, Japan
2013 Lecturer, Tohoku Medical Megabank Organization, Sendai, Miyagi, Japan
2013-2014 Research Assistant, Department of Neurology, Tohoku University Hospital, Sendai, Miyagi, Japan
2014-pres Clinical fellow, Department of Neurology, Tohoku University Hospital, Sendai, Miyagi, Japan